You note a relapse rate of 1 in every 5 years for Copaxone. but this was never shown to be true in clinical trials regulated by the FDA. In general, the "placebo effect" can account for a typical 25% efficacy. Copaxone's efficacy is a mere 29%. Rebif was a little better, so was betaseron, and avonex.
Tysabri has an efficacy of 67% and FDA clinical trials showed it does reduce relapses to 1 every 5 years.
Everyone should have the right to choose their MS drug without deception.
You note a relapse rate of 1 in every 5 years for Copaxone. but this was never shown to be true in clinical trials regulated by the FDA. In general, the "placebo effect" can account for a typical 25% efficacy. Copaxone's efficacy is a mere 29%. Rebif was a little better, so was betaseron, and avonex.
Tysabri has an efficacy of 67% and FDA clinical trials showed it does reduce relapses to 1 every 5 years.
Everyone should have the right to choose their MS drug without deception.
wendell3308 3 years ago